{"id":7595,"date":"2025-12-06T08:00:38","date_gmt":"2025-12-06T07:00:38","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7595"},"modified":"2025-12-06T15:46:59","modified_gmt":"2025-12-06T14:46:59","slug":"phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7595\/phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll\/","title":{"rendered":"Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R\/R CLL\/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)"},"content":{"rendered":"","protected":false},"template":"","post-tag":[559,760,704,673,628,594,781,858,850,595,542],"class_list":["post-7595","congress-resource","type-congress-resource","status-publish","hentry","post-tag-alpine","post-tag-american-society-of-hematology","post-tag-ash","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-ltfu","post-tag-relapsed-refractory-cll-sll","post-tag-small-lymphocytic-lymphoma","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":120,"tags":[704,760,781,594,595,850,559,858,542,628,673],"visible_tags":[704,781,542],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis report presents up to six years of follow-up for patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) treated with the BTK inhibitor zanubrutinib in the ALPINE study. Zanubrutinib continued to show durable benefits, with nearly half of patients remaining progression-free. Patients with high-risk genetic features (del(17p)) showed responses comparable to other patients in the study. Serious adverse events (AEs) were seen in 60% of patients, grade \u22653 AEs occurred in 79%, treatment-related grade \u22653 AEs in 42%, and 20% discontinued due to AEs. Fatal TEAEs occurred in 47 patients, most frequently due to infection. The safety profile remained consistent over time, with most side effects stable year-to-year. These long-term data support zanubrutinib as an effective treatment option for R\/R CLL\/SLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis report presents up to six years of follow-up for patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (R\/R CLL\/SLL) treated with the BTK inhibitor zanubrutinib in the ALPINE study. Zanubrutinib continued to show durable benefits, with nearly half of patients remaining progression-free. Patients with high-risk genetic features (del(17p)) showed responses comparable to other patients in the study. Serious adverse events (AEs) were seen in 60% of patients, grade \u22653 AEs occurred in 79%, treatment-related grade \u22653 AEs in 42%, and 20% discontinued due to AEs. Fatal TEAEs occurred in 47 patients, most frequently due to infection. The safety profile remained consistent over time, with most side effects stable year-to-year. These long-term data support zanubrutinib as an effective treatment option for R\/R CLL\/SLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/299044","authors":[6577],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R\/R CLL\/SLL): Up to 6 years of follow-up with the long-term extension (LTE1) \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Discover the ASH 2025 poster of phase 3 ALPINE LTE1 6-year long-term follow-up data of zanubrutinib in R\/R CLL\/SLL, by Constantine S. Tam et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll.jpeg\", \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/299044\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-06\",  \r\n  \"keywords\": [\"alpine lte1 long-term extension study\", \"results of zanubrutinib from ALPINE study\", \"zanubrutinib clinical trial in cll\/sll patients\", \"zanubrutinib long-term safety results\", \"phase 3 BTKi efficacy in cll\", \"alpine study\", \"phase 3 alpine data\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Constantine S. Tam, MBBS (Hons), MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R\/R CLL\/SLL): Up to 6 years of follow-up with the long-term extension (LTE1)\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R\/R CLL\/SLL): Up to 6 years of follow-up with the long-term extension (LTE1) \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Discover the ASH 2025 poster of phase 3 ALPINE LTE1 6-year long-term follow-up data of zanubrutinib in R\/R CLL\/SLL, by Constantine S. Tam et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-3-alpine-lte1-6-year-long-term-data-of-zanubrutinib-in-rr-cll-sll\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6577"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/673"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/628"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/858"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/559"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/850"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7595"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}